Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

Haematologica

Volumn 92, Issue 9, 2007, Pages 1153-1158

  Reiter, Andreas ^a   Grimwade, David ^b,c   Cross, Nicholas C P ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; IMATINIB; JANUS KINASE INHIBITOR; PD 173074; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEROID; SU 5404; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL INFILTRATION; CHROMOSOME REARRANGEMENT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CLONAL VARIATION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ENZYME ACTIVATION; EOSINOPHIL COUNT; EOSINOPHILIA; FUSION GENE; GASTROINTESTINAL TRACT; HODGKIN DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MONOTHERAPY; MYELOPROLIFERATIVE DISORDER; NERVOUS SYSTEM; PATHOGENESIS; PHENOTYPE; POINT MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EOSINOPHILIA; HUMANS; MYELOPROLIFERATIVE DISORDERS;

EID: 36348999235     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10328     Document Type: Editorial

References (41)

1. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133:468-92.
2. Gotlib J, Cross NC, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Fract Res Clin Haematol 2006;19:535-69.
3. Reiter A, Walz C, Cross NCP. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Current Drug Targets 2007;8:205-16.
4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-14.
5. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100:7830-5.
6. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87.
7. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation or FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103:8078-83.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106:2162-8.
9. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia- associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21:1183-8.
10. Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Galli A, et al. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia 2007;21:397-402.
11. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003;102:3093-6.
12. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-45.
13. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant or idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-6.
14. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734-42.
15. Roche-Lestienne C, Lepers S, Soenen-Comu V, Kahn JE, Lai JL, Hachulla E, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005;19:792-8.
16. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007;109-4635-41.
17. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graff A, Fabarius A, Haferlach T, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007; 91: 163-9.
18. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-7.
19. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter J, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7.
20. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002;107:113-22.
21. Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003;120:251-6.
22. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995;9:1628-30.
23. Macdonald D, Reiter A, Cross NCP. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101-7.
24. Bousquet M, Quelen C, De M, V, Duchayne E, Roquefeuil B, Delsol G, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005;24:7248-52.
25. Murati A, Gelsi-Boyer V, Adelaide J, Perot C, Talmant P, Giraudier S, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005;19:1692-6.
26. Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006; 20:536-7.
27. Baccarani M, Cilloni D, Rondoni M, Ottaviani F, Messa F, Merante S, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα- positive hypereosinophilic syndrome. Results of a multicenter study. Haematologica 2007;92:1173-9.
28. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006;30:965-70.
29. Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 2006;76:535-6.
30. Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003;102:3456-7.
31. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR α-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005;19:286-7.
32. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR α-induced myeloproliferative disease. Cancer Cell 2003;3:459-69.
33. Lierman E, Folens C, Stover EH, Mentens N, Van MH, Scheers W, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108:1374-6.
34. von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006; 107:4970-1.
35. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61-4.
36. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001;98:3778-83.
37. Chen J, DeAngelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:14479-84.
38. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells frornpatients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
39. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006;20:29-41.
40. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007;44:S15-S24.
41. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.